Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in children and young people.
- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Further information:
- Following on from information provided to NICE by the company in September 2018, the appraisal of Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378] was suspended from NICE’s work programme. This topic will instead be covered by the NHS England Medicines for Children policy.
- ID number:
- 1378
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 February 2023 | Topic selection. Following on from information provided to NICE by the company in September 2018, the appraisal of Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378] was suspended from NICE’s work programme. This topic will instead be covered by the NHS England Medicines for Children policy. |
| 31 May 2018 (14:00) | Scoping workshop (Manchester) |
| 22 March 2018 - 23 April 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we select topics for development, please see our page about prioritising our guidance topics